Cas:105051-87-4 (8R,9S,10R,13S,14S)-4-amino-10,13-dimethyl-9,11,12,14,15,16-hexahydro-8H-cyclopenta[a]phenanthrene-3,17-dione manufacturer & supplier

Chemical Name:(8R,9S,10R,13S,14S)-4-amino-10,13-dimethyl-9,11,12,14,15,16-hexahydro-8H-cyclopenta[a]phenanthrene-3,17-dione

CAS.NO:105051-87-4

Synonyms:4-aminoandrosta-1,4,6-trien-3,17-dione;Minamestanum [INN-Latin];Minamestanum;4-amino-androsta-1,4,6-triene-3,17-dione;Minamestane;Minamestano [INN-Spanish];Minamestano

Molecular Formula:C₁₉H₂₃NO₂

Molecular Weight:297.39100

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:499.4ºC at 760mmHg

Density:1.2g/cm3

Index of Refraction:1.606

PSA:60.16000

Exact Mass:297.17300

LogP:3.62610

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like 4-aminoandrosta-1,4,6-trien-3,17-dione chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,Minamestano physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,Minamestanum Use and application,Minamestano technical grade,usp/ep/jp grade.

Related News: The government is leveraging its large patient population to push non-domestic drugs companies to cut prices to their lowest level globally. (8R,9S,10R,13S,14S)-4-amino-10,13-dimethyl-9,11,12,14,15,16-hexahydro-8H-cyclopenta[a]phenanthrene-3,17-dione manufacturer In March 2021, Reuters reported that a former Lilly human resources officer, Amrit Mula, had identified internally some of the same violations later documented by the FDA. Mula was forced out of the company in early 2019 after Lilly executives sought to downplay her findings, according to a letter demanding compensation for damages that her attorneys sent to the company. (8R,9S,10R,13S,14S)-4-amino-10,13-dimethyl-9,11,12,14,15,16-hexahydro-8H-cyclopenta[a]phenanthrene-3,17-dione supplier In March 2021, Reuters reported that a former Lilly human resources officer, Amrit Mula, had identified internally some of the same violations later documented by the FDA. Mula was forced out of the company in early 2019 after Lilly executives sought to downplay her findings, according to a letter demanding compensation for damages that her attorneys sent to the company. (8R,9S,10R,13S,14S)-4-amino-10,13-dimethyl-9,11,12,14,15,16-hexahydro-8H-cyclopenta[a]phenanthrene-3,17-dione vendor The outlook for a cure is clouded with theoretical uncertainties and high-profile failures. Pharmaceutical giants including Johnson & Johnson, Merck and Pfizer have ditched their projects on unsatisfactory data. (8R,9S,10R,13S,14S)-4-amino-10,13-dimethyl-9,11,12,14,15,16-hexahydro-8H-cyclopenta[a]phenanthrene-3,17-dione factory The outlook for a cure is clouded with theoretical uncertainties and high-profile failures. Pharmaceutical giants including Johnson & Johnson, Merck and Pfizer have ditched their projects on unsatisfactory data.